DESCRIPTIVE ANALYSIS OF REAL-WORLD MEDICATION PATTERNS AND ONE-YEAR OUTCOMES OF ACUTE CORONARY SYNDROME PATIENTS WITH METABOLIC SYNDROME IN A TERTIARY CARE HOSPITAL
PRISCILLA PAȘC 1,2, DANIELA ELISABETA BERDEA 1, LUCIANA DOBJANSCHI 1*,
CLAUDIA TEODORA JUDEA-PUSTA 1, MIRCEA IOACHIM POPESCU 1,2
1Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania 2Emergency County Clinical Hospital of Oradea, Oradea, Romania
Download Full Article PDF
The prognostic association between metabolic syndrome (MS) and long-term survival of patients with acute coronary syndrome (ACS) in the era of intervention revascularization and high-precision medication had not yet been fully established. The latest ACS guidelines recommend the combined drug regimen, comprising acetylsalicylic acid (ASA), P2Y12 (purinergic receptor P2Y12) inhibitors, angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB), βblocker, and statin, to reduce recurrent ischemic cardiovascular events and mortality. The present study examined the prescription patterns of ACS long term-therapies among MS patients and analysed the association between guidelines medication and major adverse events. 49.44% of ACS patients included in this study received all five guidelinerecommended medications. Deaths occurred predominantly in MS patients receiving less medication, meanwhile major ischemic and bleeding events increased statistically with the number of drug combinations.